Antitumor activities of EGFR/HER2/HER4 kinase inhibitor S-222611 in the experimental brain metastases of HER2-positive breast cancer

被引：0
|
作者：
Hirata, Michinari
Tanaka, Yukari
Shinonome, Satomi
Yamada, Tomomi
Torii, Mikinori
Nezasa, Kenichi
Tanaka, Hidekazu
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4073
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors
    Baird, Richard D.
    Papa, Sophie
    Cresti, Nicola
    Hatcher, Helen
    Hogarth, Linda
    Jamal-Hanjani, Mariam
    Frenkel, Eugene P.
    Donaldson, Kirsteen
    Posner, John
    Kawabata, Izumi
    Jodrell, Duncan Ian
    Plummer, Ruth
    Spicer, James F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer
    Nafi, S. Mohd
    Kong, A.
    Gijsen, M.
    Kramer-Marek, G.
    Capala, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 126 - 126
  • [23] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Endo, Yumi
    Dong, Yu
    Kondo, Naoto
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Nishimoto, Mayumi
    Kato, Hiroyuki
    Takahashi, Satoru
    Nakanishi, Ryoichi
    Toyama, Tatsuya
    BREAST CANCER, 2016, 23 (06) : 902 - 907
  • [24] Brain metastases in HER2-positive breast cancer: challenges and opportunities
    Torrejon, Davis
    Di Cosimo, Serena
    ANNALS OF PALLIATIVE MEDICINE, 2012, 1 (03) : 195 - 197
  • [25] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Yumi Endo
    Yu Dong
    Naoto Kondo
    Nobuyasu Yoshimoto
    Tomoko Asano
    Yukari Hato
    Mayumi Nishimoto
    Hiroyuki Kato
    Satoru Takahashi
    Ryoichi Nakanishi
    Tatsuya Toyama
    Breast Cancer, 2016, 23 : 902 - 907
  • [26] HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
    Hosonaga, Mari
    Arima, Yoshimi
    Sampetrean, Oltea
    Komura, Daisuke
    Koya, Ikuko
    Sasaki, Takashi
    Sato, Eiichi
    Okano, Hideyuki
    Kudoh, Jun
    Ishikawa, Shumpei
    Saya, Hideyuki
    Ishikawa, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
  • [27] Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer
    Li, Jianzong
    Wang, Haiyang
    Li, Junjie
    Bao, Jinku
    Wu, Chuanfang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (07)
  • [28] Cytogenetic analysis of Her1/EGFR, Her2/neu, Her3, and hEr4 receptor tyrosine kinases in breast cancer
    Sassen, A.
    Rochon, J.
    Wild, P.
    Hartmann, A.
    Hofstaedter, F.
    Schwarz, S.
    Brockhoff, G.
    CYTOMETRY PART A, 2007, 71A (07) : 515 - 515
  • [29] Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
    Kanthala, Shanthi
    Banappagari, Sashikanth
    Gokhale, Ameya
    Liu, Yong-Yu
    Xin, Gu
    Zhao, Yunfeng
    Jois, Seetharama
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (06) : 702 - 714
  • [30] Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
    Ahuja, Sana
    Khan, Adil Aziz
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 262
12345